

Chapter 6:

Bibliography

- [1] B. R. Bloem, M. S. Okun, and C. Klein, "Parkinson's disease," *The Lancet*, vol. 397, no. 10291. Elsevier B.V., pp. 2284–2303, Jun. 12, 2021. doi: 10.1016/S0140-6736(21)00218-X.
- [2] L. V. Kalia and A. E. Lang, "Parkinson's disease," *The Lancet*, vol. 386, no. 9996. Lancet Publishing Group, pp. 896–912, Aug. 29, 2015. doi: 10.1016/S0140-6736(14)61393-3.
- [3] W. Poewe *et al.*, "Parkinson disease," *Nat Rev Dis Primers*, vol. 3, pp. 1–21, Mar. 2017, doi: 10.1038/nrdp.2017.13.
- [4] R. Balestrino and A. H. V. Schapira, "Parkinson disease," *European Journal of Neurology*, vol. 27, no. 1. Blackwell Publishing Ltd, pp. 27–42, Jan. 01, 2020. doi: 10.1111/ene.14108.
- [5] K. Wirdefeldt, H. O. Adami, P. Cole, D. Trichopoulos, and J. Mandel, "Epidemiology and etiology of Parkinson's disease: A review of the evidence," *European Journal of Epidemiology*, vol. 26, no. SUPPL. 1. Jun. 2011. doi: 10.1007/s10654-011-9581-6.
- [6] R. Mayeux *et al.*, "The Frequency of Idiopathic Parkinson's Disease by Age, Ethnic Group, and Sex in Northern Manhattan, 1988-1993," 1995. [Online]. Available: <https://academic.oup.com/aje/article/142/8/820/51334>
- [7] J. Benito-León, F. Bermejo-Pareja, J. Rodríguez, J. A. Molina, R. Gabriel, and J. M. Morales, "Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain," *Movement Disorders*, vol. 18, no. 3, pp. 267–274, Mar. 2003, doi: 10.1002/mds.10362.
- [8] G. F. Wooten, L. J. Currie, V. E. Bovbjerg, J. K. Lee, and J. Patrie, "Are men at greater risk for Parkinson's disease than women?," *J Neurol Neurosurg Psychiatry*, vol. 75, no. 4, pp. 637–639, Apr. 2004, doi: 10.1136/jnnp.2003.020982.
- [9] F. J. Charlson, A. J. Baxter, H. G. Cheng, R. Shidhaye, and H. A. Whiteford, "The burden of mental, neurological, and substance use disorders in China and India: a systematic analysis of community representative epidemiological studies," *The Lancet*, vol. 388, no. 10042, pp. 376–389, Jul. 2016, doi: 10.1016/S0140-6736(16)30590-6.
- [10] V. Dhiman *et al.*, "A Systematic Review and Meta-analysis of Prevalence of Epilepsy, Dementia, Headache, and Parkinson Disease in India." [Online]. Available: <https://www.neurologyindia.com/printarticle.asp?issn=0028-3886;year=2021;volume=69;issue=2;spage=294;epage=301;aualast=Dhiman>
- [11] M. Gourie-Devi, G. Gururaj, P. Satishchandra, and D. K. Subbakrishna, "Prevalence of neurological disorders in Bangalore, India: A community-based study with a comparison between urban and rural areas," *Neuroepidemiology*, vol. 23, no. 6. pp. 261–268, 2004. doi: 10.1159/000080090.
- [12] S. K. Das *et al.*, "A random sample survey for prevalence of major neurological disorders in Kolkata."
- [13] S. Razdan, R. L. Kaul, A. Motta, S. Kau, and R. K. Bhatt, "Prevalence and Pattern of Major Neurological Disorders in Rural Kashmir (India) in 1986."
- [14] G. Je *et al.*, "Epidemiology of Parkinson's Disease in Rural Gujarat, India," *Neuroepidemiology*, vol. 55, no. 3, pp. 188–195, Jun. 2021, doi: 10.1159/000515030.
- [15] N. Bharucha and *et al.*, "prevalance of PD in the parsi community of bombay india," *Arch Neurol*, vol. 45, no. 12, pp. 1321–1323, 1988.
- [16] P. Surathi, K. Jhunjhunwala, R. Yadav, and P. K. Pal, "Research in Parkinson's disease in India: A review," *Annals of Indian Academy of Neurology*, vol. 19, no. 1. Medknow Publications, pp. 9–20, Jan. 01, 2016. doi: 10.4103/0972-2327.167713.
- [17] F. Blandini, G. Nappi, C. Tassorelli, and E. Martignoni, "Functional changes of the basal ganglia circuitry in Parkinson's disease." [Online]. Available: www.elsevier.com/locate/pneurobio
- [18] K. Reetz *et al.*, "Structural findings in the Basal Ganglia in genetically determined and idiopathic Parkinson's disease," *Movement Disorders*, vol. 24, no. 1, pp. 99–103, Jan. 2009, doi: 10.1002/mds.22333.

- [19] P. Giompres and F. Delis, “Dopamine transporters in the cerebellum of mutant mice,” *Cerebellum*, vol. 4, no. 2, pp. 105–111, 2005, doi: 10.1080/14734220510007851.
- [20] P. Borghammer *et al.*, “A deformation-based morphometry study of patients with early-stage Parkinson’s disease,” *Eur J Neurol*, vol. 17, no. 2, pp. 314–320, Feb. 2010, doi: 10.1111/j.1468-1331.2009.02807.x.
- [21] G. Donzuso *et al.*, “Neuroanatomical changes in early Parkinson’s disease with mild cognitive impairment: a VBM study; the Parkinson’s Disease Cognitive Impairment Study (PaCoS),” doi: 10.1007/s10072-020-05034-9/Published.
- [22] R. Biundo *et al.*, “Brain volume changes in Parkinson’s disease and their relationship with cognitive and behavioural abnormalities,” *J Neurol Sci*, vol. 310, no. 1–2, pp. 64–69, Nov. 2011, doi: 10.1016/j.jns.2011.08.001.
- [23] E. C. Hirsch, P. Jenner, and S. Przedborski, “Pathogenesis of Parkinson’s disease,” *Movement Disorders*, vol. 28, no. 1, pp. 24–30, Jan. 2013. doi: 10.1002/mds.25032.
- [24] C. Raza, R. Anjum, and N. ul A. Shakeel, “Parkinson’s disease: Mechanisms, translational models and management strategies,” *Life Sciences*, vol. 226. Elsevier Inc., pp. 77–90, Jun. 01, 2019. doi: 10.1016/j.lfs.2019.03.057.
- [25] H. Deng, P. Wang, and J. Jankovic, “The genetics of Parkinson disease,” *Ageing Research Reviews*, vol. 42. Elsevier Ireland Ltd, pp. 72–85, Mar. 01, 2018. doi: 10.1016/j.arr.2017.12.007.
- [26] B. I. Giasson, I. V. J. Murray, J. Q. Trojanowski, and V. M. Y. Lee, “A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α -Synuclein Is Essential for Filament Assembly,” *Journal of Biological Chemistry*, vol. 276, no. 4, pp. 2380–2386, Jan. 2001, doi: 10.1074/jbc.M008919200.
- [27] J. E. Payton, R. J. Perrin, W. S. Woods, and J. M. George, “Structural determinants of PLD2 inhibition by α -synuclein,” *J Mol Biol*, vol. 337, no. 4, pp. 1001–1009, Apr. 2004, doi: 10.1016/j.jmb.2004.02.014.
- [28] A. Sidhu, C. Wersinger, C. E. H. Moussa, and P. Vernier, “The role of α -synuclein in both neuroprotection and neurodegeneration,” in *Annals of the New York Academy of Sciences*, New York Academy of Sciences, 2004, pp. 250–270. doi: 10.1196/annals.1332.016.
- [29] C. W. Bertoncini *et al.*, “Release of long-range tertiary interactions potentiates aggregation of natively unstructured-synuclein,” 2005. [Online]. Available: www.pnas.org/cgi/doi/10.1073/pnas.0407146102
- [30] H. Fujiwara *et al.*, “ α -synuclein is phosphorylated in synucleinopathy lesions,” *Nat Cell Biol*, vol. 4, no. 2, pp. 160–164, 2002, doi: 10.1038/ncb748.
- [31] I. Martin, J. W. Kim, V. L. Dawson, and T. M. Dawson, “LRRK2 pathobiology in Parkinson’s disease,” *Journal of Neurochemistry*, vol. 131, no. 5. Blackwell Publishing Ltd, pp. 554–565, 2014. doi: 10.1111/jnc.12949.
- [32] A. G. Henry *et al.*, “Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression,” *Hum Mol Genet*, vol. 24, no. 21, pp. 6013–6028, Nov. 2015, doi: 10.1093/hmg/ddv314.
- [33] H. Shimura *et al.*, “Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase,” *Nat Genet*, vol. 25, pp. 302–305, 2000, [Online]. Available: <http://genetics.nature.com>
- [34] A. J. Whitworth and L. J. Pallanck, “The PINK1/Parkin pathway: A mitochondrial quality control system?,” *Journal of Bioenergetics and Biomembranes*, vol. 41, no. 6, pp. 499–503, Dec. 2009. doi: 10.1007/s10863-009-9253-3.
- [35] D. Narendra, A. Tanaka, D. F. Suen, and R. J. Youle, “Parkin-induced mitophagy in the pathogenesis of Parkinson disease,” *Autophagy*, vol. 5, no. 5. Taylor and Francis Inc., pp. 706–708, Jul. 01, 2009. doi: 10.4161/auto.5.5.8505.
- [36] A. C. Poole *et al.*, “The PINK1/Parkin pathway regulates mitochondrial morphology,” 2008.

- [37] K. Kalinderi, S. Bostantjopoulou, and L. Fidani, "The genetic background of Parkinson's disease: current progress and future prospects," *Acta Neurologica Scandinavica*, vol. 134, no. 5. Blackwell Publishing Ltd, pp. 314–326, Nov. 01, 2016. doi: 10.1111/ane.12563.
- [38] E. M. Valente *et al.*, "Hereditary early-onset Parkinson's disease caused by mutations in PINK1," *Science (1979)*, vol. 304, no. 5674, pp. 1158–1160, May 2004, doi: 10.1126/science.1096284.
- [39] M. Seirafi, G. Kozlov, and K. Gehring, "Parkin structure and function," *FEBS Journal*, vol. 282, no. 11. Blackwell Publishing Ltd, pp. 2076–2088, Jun. 01, 2015. doi: 10.1111/febs.13249.
- [40] E. Junn, H. Taniguchi, B. Seon Jeong, X. Zhao, H. Ichijo, and M. Maral Mouradian, "Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death," 2005. [Online]. Available: www.pnas.org/cgi/doi/10.1073/pnas.0409635102
- [41] D. J. Moore, L. Zhang, T. M. Dawson, and V. L. Dawson, "A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homooligomerization", doi: 10.1046/j.1471-4159.2003.02265.x.
- [42] K. Takahashi-Niki, T. Niki, T. Taira, S. M. M. Iguchi-Arigo, and H. Ariga, "Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients," *Biochem Biophys Res Commun*, vol. 320, no. 2, pp. 389–397, Jul. 2004, doi: 10.1016/j.bbrc.2004.05.187.
- [43] C. Klein, S. A. Schneider, and A. E. Lang, "Hereditary Parkinsonism: Parkinson disease look-alikes - An algorithm for clinicians to 'PARK' genes and beyond," *Movement Disorders*, vol. 24, no. 14. pp. 2042–2058, Oct. 30, 2009. doi: 10.1002/mds.22675.
- [44] C. Klein and A. Westenberger, "Genetics of Parkinson's disease," *Cold Spring Harb Perspect Med*, vol. 2, no. 1, 2012, doi: 10.1101/cshperspect.a008888.
- [45] A. Brice, "Genetics of Parkinson's disease: LRRK2 on the rise," *Brain*, vol. 128, no. 12. Oxford University Press, pp. 2760–2762, 2005. doi: 10.1093/brain/awh676.
- [46] L. Ozelius and et.al, "LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews," *New England Journal of Medicine*, vol. 354, no. 4, pp. 424–425, 2006.
- [47] K. Nuytemans, J. Theuns, M. Cruts, and C. Van Broeckhoven, "Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update," *Human Mutation*, vol. 31, no. 7. Wiley-Liss Inc., pp. 763–780, 2010. doi: 10.1002/humu.21277.
- [48] D. G. Healy *et al.*, "PINK1 (PARK6) associated Parkinson disease in Ireland," *Neurology*, vol. 63, no. 8, pp. 1486–1488, Oct. 2004, doi: 10.1212/01.WNL.0000142089.38301.8E.
- [49] E. M. Valente *et al.*, "PINK1 mutations are associated with sporadic early-onset Parkinsonism," *Ann Neurol*, vol. 56, no. 3, pp. 336–341, Sep. 2004, doi: 10.1002/ana.20256.
- [50] E. Rogaeva *et al.*, "Analysis of the PINK1 Gene in a Large Cohort of Cases With Parkinson Disease."
- [51] Y. H. Weng *et al.*, "PINK1 mutation in Taiwanese early-onset parkinsonism: Clinical, genetic, and dopamine transporter studies," *J Neurol*, vol. 254, no. 10, pp. 1347–1355, Oct. 2007, doi: 10.1007/s00415-007-0534-7.
- [52] I. F. Mata, P. J. Lockhart, and M. J. Farrer, "Parkin genetics: One model for Parkinson's disease," *Human Molecular Genetics*, vol. 13, no. REV. ISS. 1. Apr. 01, 2004. doi: 10.1093/hmg/ddh089.
- [53] E. M. Valente *et al.*, "Localization of a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, PARK6, on Human Chromosome 1p35-p36," 2001.
- [54] Y. Miyake *et al.*, "UCHL1 S18Y variant is a risk factor for Parkinson's disease in Japan," *BMC Neurol*, vol. 12, Jul. 2012, doi: 10.1186/1471-2377-12-62.
- [55] J. yong Tian *et al.*, "Mutation analysis of LRRK2, SCNA, UCHL1, HtrA2 and GIGYF2 genes in Chinese patients with autosomal dominant Parkinson's disease," *Neurosci Lett*, vol. 516, no. 2, pp. 207–211, May 2012, doi: 10.1016/j.neulet.2012.03.086.

- [56] T. Shen *et al.*, “Genetic analysis of ATP13A2, PLA2G6 and FBXO7 in a cohort of Chinese patients with early-onset Parkinson’s disease,” *Sci Rep*, vol. 8, no. 1, Dec. 2018, doi: 10.1038/s41598-018-32217-4.
- [57] Q. Z. Fei *et al.*, “Lack of association between ATP13A2 Ala746Thr variant and Parkinson’s disease in Han population of mainland China,” *Neurosci Lett*, vol. 475, no. 2, pp. 61–63, May 2010, doi: 10.1016/j.neulet.2010.03.018.
- [58] C. Lautier *et al.*, “Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease,” *Am J Hum Genet*, vol. 82, no. 4, pp. 822–833, Apr. 2008, doi: 10.1016/j.ajhg.2008.01.015.
- [59] Y. C. He *et al.*, “Mutation Analysis of HTRA2 Gene in Chinese Familial Essential Tremor and Familial Parkinson’s Disease,” *Parkinsons Dis*, vol. 2017, 2017, doi: 10.1155/2017/3217474.
- [60] K. M. Strauss *et al.*, “Loss of function mutations in the gene encoding Omi/Htra2 in Parkinson’s disease,” *Hum Mol Genet*, vol. 14, no. 15, pp. 2099–2111, Aug. 2005, doi: 10.1093/hmg/ddi215.
- [61] K. Daida *et al.*, “PLA2G6 variants associated with the number of affected alleles in Parkinson’s disease in Japan,” *Neurobiol Aging*, vol. 97, pp. 147.e1-147.e9, Jan. 2021, doi: 10.1016/j.neurobiolaging.2020.07.004.
- [62] Y. X. Gui, Z. P. Xu, Wen-Lv, H. M. Liu, J. J. Zhao, and X. Y. Hu, “Four novel rare mutations of PLA2G6 in Chinese population with Parkinson’s disease,” *Parkinsonism Relat Disord*, vol. 19, no. 1, pp. 21–26, Jan. 2013, doi: 10.1016/j.parkreldis.2012.07.016.
- [63] C. H. Lin, M. L. Chen, T. T. Lai, C. H. Tai, and R. M. Wu, “Mutational analysis of FBXO7 gene in Parkinson’s disease in a Taiwanese population,” *Neurobiol Aging*, vol. 34, no. 6, pp. 1713.e1-1713.e4, 2013, doi: 10.1016/j.neurobiolaging.2012.12.023.
- [64] P. Gómez-Garre *et al.*, “Systematic mutational analysis of FBXO7 in a Parkinson’s disease population from southern Spain,” *Neurobiol Aging*, vol. 35, no. 3, pp. 727.e5-727.e7, 2014, doi: 10.1016/j.neurobiolaging.2013.09.011.
- [65] A. Verstraeten *et al.*, “Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian population,” *Neurobiol Aging*, vol. 33, no. 8, pp. 1844.e11-1844.e13, 2012, doi: 10.1016/j.neurobiolaging.2012.01.006.
- [66] Y. Zhang *et al.*, “Vacuolar protein sorting 35 Asp620Asn mutation is rare in the ethnic Chinese population with Parkinson’s disease,” *Parkinsonism Relat Disord*, vol. 18, no. 5, pp. 638–640, Jun. 2012, doi: 10.1016/j.parkreldis.2012.02.011.
- [67] J. Huttenlocher *et al.*, “EIF4G1 is neither a strong nor a common risk factor for Parkinson’s disease: Evidence from large European cohorts,” *J Med Genet*, vol. 52, no. 1, pp. 37–41, 2015, doi: 10.1136/jmedgenet-2014-102570.
- [68] Y. Ma, D. Zheng, and H. Li, “Association analysis of EIF4G1 and Parkinson disease in Xinjiang Uygur and Han nationality,” *Medicine (United States)*, vol. 97, no. 18, May 2018, doi: 10.1097/MD.00000000000010234.
- [69] M. Gagliardi, G. Annesi, P. Tarantino, G. Nicoletti, and A. Quattrone, “Frequency of the ASP620ASN mutation in VPS35 and Arg1205His mutation in EIF4G1 in familial Parkinson’s disease from South Italy,” *Neurobiol Aging*, vol. 35, no. 10, pp. 2422.e1-2422.e2, 2014, doi: 10.1016/j.neurobiolaging.2014.04.020.
- [70] C. E. Krebs *et al.*, “The sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive parkinsonism with generalized seizures,” *Hum Mutat*, vol. 34, no. 9, pp. 1200–1207, Sep. 2013, doi: 10.1002/humu.22372.
- [71] W. Yan *et al.*, “TMEM230 mutation analysis in Parkinson’s disease in a Chinese population,” *Neurobiol Aging*, vol. 49, pp. 219.e1-219.e3, Jan. 2017, doi: 10.1016/j.neurobiolaging.2016.10.007.
- [72] C. Tejera-Parrado *et al.*, “TMEM230 in Parkinson’s disease in a southern Spanish population,” *PLoS One*, vol. 13, no. 5, May 2018, doi: 10.1371/journal.pone.0197271.

- [73] Q. Wei *et al.*, “TMEM230 Mutations Are Rare in Han Chinese Patients with Autosomal Dominant Parkinson’s Disease,” *Mol Neurobiol*, vol. 55, no. 4, pp. 2851–2855, Apr. 2018, doi: 10.1007/s12035-017-0542-2.
- [74] S. Kumar *et al.*, “Novel and reported variants in Parkinson’s disease genes confer high disease burden among Indians,” *Parkinsonism Relat Disord*, vol. 78, pp. 46–52, Sep. 2020, doi: 10.1016/j.parkreldis.2020.07.014.
- [75] Z. Liu *et al.*, “Mutation analysis of CHCHD2 gene in Chinese familial Parkinson’s disease,” *Neurobiol Aging*, vol. 36, no. 11, pp. 3117.e7-3117.e8, Nov. 2015, doi: 10.1016/j.neurobiolaging.2015.08.010.
- [76] M. Gagliardi, G. Iannello, C. Colica, G. Annesi, and A. Quattrone, “Analysis of CHCHD2 gene in familial Parkinson’s disease from Calabria,” *Neurobiol Aging*, vol. 50, pp. 169.e5-169.e6, Feb. 2017, doi: 10.1016/j.neurobiolaging.2016.10.022.
- [77] T. Safaralizadeh *et al.*, “SIPA1L2, MIR4697, GCH1 and VPS13C loci and risk of Parkinson’s diseases in Iranian population: A case-control study,” *J Neurol Sci*, vol. 369, pp. 1–4, Oct. 2016, doi: 10.1016/j.jns.2016.08.001.
- [78] X. Gu *et al.*, “Mutation screening and burden analysis of VPS13C in Chinese patients with early-onset Parkinson’s disease,” *Neurobiol Aging*, vol. 94, pp. 311.e1-311.e4, Oct. 2020, doi: 10.1016/j.neurobiolaging.2020.05.005.
- [79] S. E. Winder-Rhodes *et al.*, “Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort,” *Brain*, vol. 136, no. 2, pp. 392–399, 2013, doi: 10.1093/brain/aws318.
- [80] K. R. Kumar *et al.*, “Glucocerebrosidase mutations in a Serbian Parkinson’s disease population,” *Eur J Neurol*, vol. 20, no. 2, pp. 402–405, Feb. 2013, doi: 10.1111/j.1468-1331.2012.03817.x.
- [81] E. Gelpi *et al.*, “Multiple organ involvement by alpha-synuclein pathology in lewy body disorders,” *Movement Disorders*, vol. 29, no. 8, pp. 1010–1018, 2014, doi: 10.1002/mds.25776.
- [82] H. Braak, K. Del Tredici, U. Rüb, R. A. I. De Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson’s disease,” *Neurobiol Aging*, vol. 24, no. 2, pp. 197–211, Mar. 2003, doi: 10.1016/S0197-4580(02)00065-9.
- [83] A. Bloch, A. Probst, H. Bissig, H. Adams, and M. Tolnay, “ α -Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects,” *Neuropathol Appl Neurobiol*, vol. 32, no. 3, pp. 284–295, Jun. 2006, doi: 10.1111/j.1365-2990.2006.00727.x.
- [84] G. Halliday, H. McCann, and C. Shepherd, “Evaluation of the Braak hypothesis: How far can it explain the pathogenesis of Parkinson’s disease?,” *Expert Review of Neurotherapeutics*, vol. 12, no. 6, pp. 673–686, Jun. 2012. doi: 10.1586/ern.12.47.
- [85] I. Alafuzoff *et al.*, “Staging/typing of Lewy body related α -synuclein pathology: A study of the BrainNet Europe Consortium,” *Acta Neuropathol*, vol. 117, no. 6, pp. 635–652, 2009, doi: 10.1007/s00401-009-0523-2.
- [86] J. Y. Li *et al.*, “Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation,” *Nat Med*, vol. 14, no. 5, pp. 501–503, May 2008, doi: 10.1038/nm1746.
- [87] R. C. Paolicelli *et al.*, “Synaptic pruning by microglia is necessary for normal brain development,” *Science (1979)*, vol. 333, no. 6048, pp. 1456–1458, Sep. 2011, doi: 10.1126/science.1202529.
- [88] S. Jäkel and L. Dimou, “Glial cells and their function in the adult brain: A journey through the history of their ablation,” *Frontiers in Cellular Neuroscience*, vol. 11. Frontiers Research Foundation, Feb. 13, 2017. doi: 10.3389/fncel.2017.00024.
- [89] J. H. Lee *et al.*, “Astrocytes phagocytose adult hippocampal synapses for circuit homeostasis,” *Nature*, vol. 590, no. 7847, pp. 612–617, Feb. 2021, doi: 10.1038/s41586-020-03060-3.

- [90] A. Schnatz, C. Müller, A. Brahmer, and E. M. Krämer-Albers, “Extracellular Vesicles in neural cell interaction and CNS homeostasis,” *FASEB BioAdvances*, vol. 3, no. 8. John Wiley and Sons Inc, pp. 577–592, Aug. 01, 2021. doi: 10.1096/fba.2021-00035.
- [91] E. C. Hirsch and S. Hunot, “Neuroinflammation in Parkinson’s disease: a target for neuroprotection?,” *The Lancet Neurology*, vol. 8, no. 4. pp. 382–397, Apr. 2009. doi: 10.1016/S1474-4422(09)70062-6.
- [92] M. Chivet, C. Javalet, K. Laulagnier, B. Blot, F. J. Hemming, and R. Sadoul, “Exosomes secreted by cortical neurons upon glutamatergic synapse activation specifically interact with neurons,” *J Extracell Vesicles*, vol. 3, no. 1, 2014, doi: 10.3402/jev.v3.24722.
- [93] G. Lachenal *et al.*, “Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity,” *Molecular and Cellular Neuroscience*, vol. 46, no. 2, pp. 409–418, Feb. 2011, doi: 10.1016/j.mcn.2010.11.004.
- [94] I. Bahrini, J. H. Song, D. Diez, and R. Hanayama, “Neuronal exosomes facilitate synaptic pruning by up-regulating complement factors in microglia,” *Sci Rep*, vol. 5, 2015, doi: 10.1038/srep07989.
- [95] S. J. Hewett, N. A. J. #2, and R. J. Claycomb, “Interleukin-1 β in Central Nervous System Injury and Repair.”
- [96] R. Pascua-Maestro, S. Diez-Hernando, C. Lillo, M. D. Ganfornina, and D. Sanchez, “Protecting cells by protecting their vulnerable lysosomes: Identification of a new mechanism for preserving lysosomal functional integrity upon oxidative stress,” *PLoS Genet*, vol. 13, no. 2, Feb. 2017, doi: 10.1371/journal.pgen.1006603.
- [97] R. Pascua-Maestro, E. González, C. Lillo, M. D. Ganfornina, J. M. Falcón-Pérez, and D. Sanchez, “Extracellular vesicles secreted by astroglial cells transport apolipoprotein D to neurons and mediate neuronal survival upon oxidative stress,” *Front Cell Neurosci*, vol. 12, Jan. 2019, doi: 10.3389/fncel.2018.00526.
- [98] S. Wang *et al.*, “Synapsin I is an oligomannose-carrying glycoprotein, acts as an oligomannose-binding lectin, and promotes neurite outgrowth and neuronal survival when released via glia-derived exosomes,” *Journal of Neuroscience*, vol. 31, no. 20, pp. 7275–7290, 2011, doi: 10.1523/JNEUROSCI.6476-10.2011.
- [99] C. Frühbeis *et al.*, “Neurotransmitter-Triggered Transfer of Exosomes Mediates Oligodendrocyte-Neuron Communication,” *PLoS Biol*, vol. 11, no. 7, Jul. 2013, doi: 10.1371/journal.pbio.1001604.
- [100] E. M. Krämer-Albers *et al.*, “Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: Trophic support for axons?,” *Proteomics Clin Appl*, vol. 1, no. 11, pp. 1446–1461, Nov. 2007, doi: 10.1002/prca.200700522.
- [101] L. J. Vella, R. A. Sharples, V. A. Lawson, C. L. Masters, R. Cappai, and A. F. Hill, “Packaging of prions into exosomes is associated with a novel pathway of PrP processing,” *Journal of Pathology*, vol. 211, no. 5, pp. 582–590, Apr. 2007, doi: 10.1002/path.2145.
- [102] H. J. Lee, S. Patel, and S. J. Lee, “Intravesicular localization and exocytosis of α -synuclein and its aggregates,” *Journal of Neuroscience*, vol. 25, no. 25, pp. 6016–6024, Jul. 2005, doi: 10.1523/JNEUROSCI.0692-05.2005.
- [103] E. Emmanouilidou *et al.*, “Cell-produced α -synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival,” *Journal of Neuroscience*, vol. 30, no. 20, pp. 6838–6851, May 2010, doi: 10.1523/JNEUROSCI.5699-09.2010.
- [104] K. J. Vargas, S. Makani, T. Davis, C. H. Westphal, P. E. Castillo, and S. S. Chandra, “Synucleins regulate the kinetics of synaptic vesicle endocytosis,” *Journal of Neuroscience*, vol. 34, no. 28, pp. 9364–9376, 2014, doi: 10.1523/JNEUROSCI.4787-13.2014.
- [105] J. Cisneros, T. B. Belton, G. C. Shum, C. G. Molakal, and Y. C. Wong, “Mitochondria-lysosome contact site dynamics and misregulation in neurodegenerative diseases,” *Trends in Neurosciences*, vol. 45, no. 4. Elsevier Ltd, pp. 312–322, Apr. 01, 2022. doi: 10.1016/j.tins.2022.01.005.

- [106] S. Paillusson *et al.*, “There’s Something Wrong with my MAM; the ER-Mitochondria Axis and Neurodegenerative Diseases,” *Trends in Neurosciences*, vol. 39, no. 3. Elsevier Ltd, pp. 146–157, Mar. 01, 2016. doi: 10.1016/j.tins.2016.01.008.
- [107] C. Parrado-Fernández *et al.*, “Reduction of PINK1 or DJ-1 impair mitochondrial motility in neurites and alter ER-mitochondria contacts,” *J Cell Mol Med*, vol. 22, no. 11, pp. 5439–5449, Nov. 2018, doi: 10.1111/jcmm.13815.
- [108] V. Basso *et al.*, “Regulation of ER-mitochondria contacts by Parkin via Mfn2,” *Pharmacol Res*, vol. 138, pp. 43–56, Dec. 2018, doi: 10.1016/j.phrs.2018.09.006.
- [109] S. Kim, Y. C. Wong, F. Gao, and D. Krainc, “Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson’s disease,” *Nat Commun*, vol. 12, no. 1, Dec. 2021, doi: 10.1038/s41467-021-22113-3.
- [110] J. M. Cioni *et al.*, “Late Endosomes Act as mRNA Translation Platforms and Sustain Mitochondria in Axons,” *Cell*, vol. 176, no. 1–2, pp. 56–72.e15, Jan. 2019, doi: 10.1016/j.cell.2018.11.030.
- [111] P. Rivero-Ríos, M. Romo-Lozano, B. Fernández, E. Fdez, and S. Hilfiker, “Distinct Roles for RAB10 and RAB29 in Pathogenic LRRK2-Mediated Endolysosomal Trafficking Alterations,” *Cells*, vol. 9, no. 7, Jul. 2020, doi: 10.3390/cells9071719.
- [112] C. M. Lill *et al.*, “Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDgene database,” *PLoS Genet*, vol. 8, no. 3, Mar. 2012, doi: 10.1371/journal.pgen.1002548.
- [113] A. Muraleedharan and B. Vanderperre, “The Endo-lysosomal System in Parkinson’s Disease: Expanding the Horizon,” *Journal of Molecular Biology*, vol. 435, no. 12. Academic Press, Jun. 15, 2023. doi: 10.1016/j.jmb.2023.168140.
- [114] K. J. Lin *et al.*, “The overcrowded crossroads: Mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson’s disease,” *International Journal of Molecular Sciences*, vol. 20, no. 21. MDPI AG, Nov. 01, 2019. doi: 10.3390/ijms20215312.
- [115] M. Teixeira, R. Sheta, W. Idi, and A. Oueslati, “Alpha-synuclein and the endolysosomal system in parkinson’s disease: Guilty by association,” *Biomolecules*, vol. 11, no. 9. MDPI, Sep. 01, 2021. doi: 10.3390/biom11091333.
- [116] M. P. Murphy, “How mitochondria produce reactive oxygen species,” *Biochemical Journal*, vol. 417, no. 1. pp. 1–13, Jan. 01, 2009. doi: 10.1042/BJ20081386.
- [117] A. A. Starkov, “The role of mitochondria in reactive oxygen species metabolism and signaling,” in *Annals of the New York Academy of Sciences*, Blackwell Publishing Inc., 2008, pp. 37–52. doi: 10.1196/annals.1427.015.
- [118] A. H. V. Schapira, J. M. Cooper, D. Dexter, J. B. Clark, P. Jenner, and C. D. Marsden, “Mitochondrial Complex I Deficiency in Parkinson’s Disease,” *J Neurochem*, vol. 54, no. 3, pp. 823–827, 1990, doi: 10.1111/j.1471-4159.1990.tb02325.x.
- [119] W. D. Parker, J. K. Parks, and R. H. Swerdlow, “Complex I deficiency in Parkinson’s disease frontal cortex,” *Brain Res*, vol. 1189, no. 1, pp. 215–218, Jan. 2008, doi: 10.1016/j.brainres.2007.10.061.
- [120] Y. Mizuno *et al.*, “DEFICIENCIES IN COMPLEX I SUBUNITS OF THE RESPIRATORY CHAIN IN PARKINSON’S DISEASE,” *Biochemical and Biophysical Research*, vol. 163, no. 3, pp. 1450–1455, 1989.
- [121] O. Blin *et al.*, “Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson’s disease and multiple system atrophy,” 1994.
- [122] R. Betarbet and et.al., “Chronic systemic pesticide exposure reproduces features of Parkinson’s Disease,” *Nat Neurosci*, vol. 3, no. 12, pp. 1301–1306, 2000.
- [123] J. William Langston, P. Ballard, J. W. Tetrad, and I. Irwin, “Chronic parkinsonism in humans due to a product of meperidine-analog synthesis,” *Science (1979)*, vol. 219, no. 4587, pp. 979–980, 1983, doi: 10.1126/science.6823561.

- [124] C. Perier *et al.*, “Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage,” 2005. [Online]. Available: www.pnas.org/cgi/doi/10.1073/pnas.0508215102
- [125] W. Dauer and S. Przedborski, “Parkinson’s Disease : mechanisms and models,” *Neuron*, vol. 39, pp. 889–909, 2003.
- [126] E. Andres-Mateos *et al.*, “DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase,” 2007. [Online]. Available: www.pnas.org/cgi/doi/10.1073/pnas.0703219104
- [127] A. K. Reeve, K. J. Krishnan, and D. Turnbull, “Mitochondrial DNA mutations in disease, aging, and neurodegeneration,” in *Annals of the New York Academy of Sciences*, Blackwell Publishing Inc., 2008, pp. 21–29. doi: 10.1196/annals.1427.016.
- [128] T. Ozawa, “Genetic and Functional Changes in Mitochondria Associated With Aging,” 1997.
- [129] M. Gu, J. M. Cooper, J. W. Taanman, and A. H. V. Schapira, “Mitochondrial DNA transmission of the mitochondrial defect in Parkinson’s disease,” *Ann Neurol*, vol. 44, no. 2, pp. 177–186, 1998, doi: 10.1002/ana.410440207.
- [130] P. A. Trimmer, M. K. Borland, P. M. Keeney, J. P. Bennett, and W. D. Parker, “Parkinson’s disease transgenic mitochondrial cybrids generate Lewy inclusion bodies,” *J Neurochem*, vol. 88, no. 4, pp. 800–812, 2004, doi: 10.1046/j.1471-4159.2003.02168.x.
- [131] L. Petri and et al, “Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study,” *Mechanisms of Disease (Lancet)*, vol. 364, pp. 875–882, 2004, [Online]. Available: www.thelancet.com
- [132] A. Bender *et al.*, “High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease,” *Nat Genet*, vol. 38, no. 5, pp. 515–517, May 2006, doi: 10.1038/ng1769.
- [133] T. Hoang *et al.*, “Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease,” *Free Radic Biol Med*, vol. 47, no. 7, pp. 1049–1056, Oct. 2009, doi: 10.1016/j.freeradbiomed.2009.07.013.
- [134] M. I. Ekstrand *et al.*, “Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons,” 2007. [Online]. Available: www.pnas.org/cgi/doi/10.1073/pnas.0605208103
- [135] M. Gleichmann and M. P. Mattson, “Neuronal Calcium Homeostasis and Dysregulation.”
- [136] D. De Stefani, A. Raffaello, E. Teardo, I. Szabó, and R. Rizzuto, “A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter,” *Nature*, vol. 476, no. 7360, pp. 336–340, Aug. 2011, doi: 10.1038/nature10230.
- [137] J. N. Guzman *et al.*, “Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1,” *Nature*, vol. 468, no. 7324, pp. 696–700, Dec. 2010, doi: 10.1038/nature09536.
- [138] C. S. Chan *et al.*, “‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease,” *Nature*, vol. 447, no. 7148, pp. 1081–1086, Jun. 2007, doi: 10.1038/nature05865.
- [139] X. J. Wang and J. X. Xu, “Possible involvement of Ca²⁺ signaling in rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells,” *Neurosci Lett*, vol. 376, no. 2, pp. 127–132, Mar. 2005, doi: 10.1016/j.neulet.2004.11.041.
- [140] S. C. Sousa, E. N. Maciel, A. E. Vercesi, and R. F. Castilho, “Ca²⁺-induced oxidative stress in brain mitochondria treated with the respiratory chain inhibitor rotenone,” *FEBS Lett*, vol. 543, no. 1–3, pp. 179–183, May 2003, doi: 10.1016/S0014-5793(03)00421-6.
- [141] S. Gandhi *et al.*, “PINK1-Associated Parkinson’s Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death,” *Mol Cell*, vol. 33, no. 5, pp. 627–638, Mar. 2009, doi: 10.1016/j.molcel.2009.02.013.
- [142] M. C. Maiuri, E. Zalckvar, A. Kimchi, and G. Kroemer, “Self-eating and self-killing: Crosstalk between autophagy and apoptosis,” *Nature Reviews Molecular Cell Biology*, vol. 8, no. 9, pp. 741–752, Sep. 2007. doi: 10.1038/nrm2239.

- [143] L. He *et al.*, “Autophagy: The last defense against cellular nutritional stress,” *Advances in Nutrition*, vol. 9, no. 4. Oxford University Press, pp. 493–504, Jul. 01, 2018. doi: 10.1093/ADVANCES/NMY011.
- [144] B. R. Malik, D. C. Maddison, G. A. Smith, and O. M. Peters, “Autophagic and endo-lysosomal dysfunction in neurodegenerative disease,” *Molecular Brain*, vol. 12, no. 1. BioMed Central Ltd., Nov. 29, 2019. doi: 10.1186/s13041-019-0504-x.
- [145] T. Hara *et al.*, “Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice,” *Nature*, vol. 441, no. 7095, pp. 885–889, Jun. 2006, doi: 10.1038/nature04724.
- [146] M. Komatsu *et al.*, “Loss of autophagy in the central nervous system causes neurodegeneration in mice,” *Nature*, vol. 441, no. 7095, pp. 880–884, Jun. 2006, doi: 10.1038/nature04723.
- [147] A. maria Cuervo and et al, “Impaired Degradation of Mutant alpha-Synuclein by Chaperone-Mediated Autophagy,” *Science (1979)*, vol. 305, no. 5688, pp. 1289–1292, Aug. 2004, doi: 10.1126/science.1101372.
- [148] T. Vogiatzi, M. Xilouri, K. Vekrellis, and L. Stefanis, “Wild type α -synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells,” *Journal of Biological Chemistry*, vol. 283, no. 35, pp. 23542–23556, Aug. 2008, doi: 10.1074/jbc.M801992200.
- [149] K. Wang, J. Huang, W. Xie, L. Huang, C. Zhong, and Z. Chen, “Beclin1 and HMGB1 ameliorate the $\alpha\alpha$ -synuclein-mediated autophagy inhibition in PC12 cells,” *Diagn Pathol*, vol. 11, no. 1, Jan. 2016, doi: 10.1186/s13000-016-0459-5.
- [150] K. E. Murphy *et al.*, “Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson’s disease,” *Movement Disorders*, vol. 30, no. 12, pp. 1639–1647, Oct. 2015, doi: 10.1002/mds.26141.
- [151] S. J. Orenstein *et al.*, “Interplay of LRRK2 with chaperone-mediated autophagy,” *Nat Neurosci*, vol. 16, no. 4, pp. 394–406, Apr. 2013, doi: 10.1038/nn.3350.
- [152] J. M. Y. Teves *et al.*, “Parkinson’s disease skin fibroblasts display signature alterations in growth, redox homeostasis, mitochondrial function, and autophagy,” *Front Neurosci*, vol. 11, no. JAN, Jan. 2018, doi: 10.3389/fnins.2017.00737.
- [153] C. Gómez-Santos, I. Ferrer, A. F. Santidrián, M. Barrachina, J. Gil, and S. Ambrosio, “Dopamine induces autophagic cell death and α -synuclein increase in human neuroblastoma SH-SY5Y cells,” *J Neurosci Res*, vol. 73, no. 3, pp. 341–350, Aug. 2003, doi: 10.1002/jnr.10663.
- [154] S. M. S. Yakhine-Diop *et al.*, “The parkinsonian LRRK2 R1441G mutation shows macroautophagy-mitophagy dysregulation concomitant with endoplasmic reticulum stress,” *Cell Biol Toxicol*, vol. 38, no. 5, pp. 889–911, Oct. 2022, doi: 10.1007/s10565-021-09617-w.
- [155] M. Miyara and et al, “Mild MPP+ exposure impairs autophagic degradation through a novel lysosomal acidity-independent mechanism,” *J Neurochem*, vol. 139, no. 2, Oct. 2016, doi: 10.1111/jnc.13338.
- [156] M. Xilouri, T. Vogiatzi, K. Vekrellis, D. Park, and L. Stefanis, “Abberant α -synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy,” *PLoS One*, vol. 4, no. 5, May 2009, doi: 10.1371/journal.pone.0005515.
- [157] F. Hopfner *et al.*, “Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson’s Disease,” *Movement Disorders*, vol. 35, no. 7, pp. 1245–1248, Jul. 2020, doi: 10.1002/mds.28037.
- [158] C. H. Adler *et al.*, “GBA mutations in Parkinson disease: earlier death but similar neuropathological features,” *Eur J Neurol*, vol. 24, no. 11, pp. 1363–1368, Nov. 2017, doi: 10.1111/ene.13395.
- [159] E. M. Rocha *et al.*, “Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α -Synuclein Aggregation, Microglia and Complement C1q Activation in Mice,” *Antioxid Redox Signal*, vol. 23, no. 6, pp. 550–564, Aug. 2015, doi: 10.1089/ars.2015.6307.
- [160] K. E. Murphy *et al.*, “Reduced glucocerebrosidase is associated with increased α -synuclein in sporadic Parkinson’s disease,” *Brain*, vol. 137, no. 3, pp. 834–848, 2014, doi: 10.1093/brain/awt367.

- [161] E. M. Rocha *et al.*, “Progressive decline of glucocerebrosidase in aging and Parkinson’s disease,” *Ann Clin Transl Neurol*, vol. 2, no. 4, pp. 433–438, Apr. 2015, doi: 10.1002/ACN3.177.
- [162] S. Yu Yang, M. Gegg, D. Chau, and A. Schapira, “Glucocerebrosidase activity, cathepsin D and monomeric α -synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation,” *Neurobiol Dis*, vol. 134, Feb. 2020, doi: 10.1016/j.nbd.2019.104620.
- [163] B. Dehay *et al.*, “Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration,” *Proc Natl Acad Sci U S A*, vol. 109, no. 24, pp. 9611–9616, Jun. 2012, doi: 10.1073/pnas.1112368109.
- [164] F. Guerra *et al.*, “Synergistic effect of mitochondrial and lysosomal dysfunction in parkinson’s disease,” *Cells*, vol. 8, no. 5, May 2019, doi: 10.3390/cells8050452.
- [165] I. Kim, S. Rodriguez-Enriquez, and J. J. Lemasters, “Selective degradation of mitochondria by mitophagy,” *Archives of Biochemistry and Biophysics*, vol. 462, no. 2, pp. 245–253, Jun. 15, 2007, doi: 10.1016/j.abb.2007.03.034.
- [166] S. W. G. Tait and D. R. Green, “Mitochondria and cell death: Outer membrane permeabilization and beyond,” *Nature Reviews Molecular Cell Biology*, vol. 11, no. 9, pp. 621–632, Sep. 2010, doi: 10.1038/nrm2952.
- [167] C. Vives-Bauza and S. Przedborski, “Mitophagy: The latest problem for Parkinson’s disease,” *Trends in Molecular Medicine*, vol. 17, no. 3, pp. 158–165, Mar. 2011, doi: 10.1016/j.molmed.2010.11.002.
- [168] H. Deng, M. W. Dodson, H. Huang, and M. Guo, “The Parkinson’s disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in *Drosophila*,” 2008. [Online]. Available: www.pnas.org/cgi/doi/10.1073/pnas.0803998105
- [169] D. Narendra, A. Tanaka, D. F. Suen, and R. J. Youle, “Parkin is recruited selectively to impaired mitochondria and promotes their autophagy,” *Journal of Cell Biology*, vol. 183, no. 5, pp. 795–803, Dec. 2008, doi: 10.1083/jcb.200809125.
- [170] R. K. Dagda, S. J. Cherra, S. M. Kulich, A. Tandon, D. Park, and C. T. Chu, “Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission,” *Journal of Biological Chemistry*, vol. 284, no. 20, pp. 13843–13855, May 2009, doi: 10.1074/jbc.M808515200.
- [171] B. Dehay *et al.*, “Pathogenic lysosomal depletion in Parkinson’s disease,” *Journal of Neuroscience*, vol. 30, no. 37, pp. 12535–12544, Sep. 2010, doi: 10.1523/JNEUROSCI.1920-10.2010.
- [172] M. Vila, J. Bové, B. Dehay, N. Rodríguez-Muela, and P. Boya, “Lysosomal membrane permeabilization in Parkinson disease,” *Autophagy*, vol. 7, no. 1, Taylor and Francis Inc., pp. 98–100, 2011, doi: 10.4161/auto.7.1.13933.
- [173] S. Y. Chung *et al.*, “Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α -Synuclein Accumulation,” *Stem Cell Reports*, vol. 7, no. 4, pp. 664–677, Oct. 2016, doi: 10.1016/j.stemcr.2016.08.012.
- [174] A. Siddiqui *et al.*, “Mitochondrial quality control via the PGC1 α -TFEB signaling pathway is compromised by parkin Q311X mutation but independently restored by rapamycin,” *Journal of Neuroscience*, vol. 35, no. 37, pp. 12833–12844, Sep. 2015, doi: 10.1523/JNEUROSCI.0109-15.2015.
- [175] Y. C. Wong, D. Ysselstein, and D. Krainc, “Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis,” *Nature*, vol. 554, no. 7692, pp. 382–386, Feb. 2018, doi: 10.1038/nature25486.
- [176] F. Baixauli, C. López-Otín, and M. Mittelbrunn, “Exosomes and autophagy: Coordinated mechanisms for the maintenance of cellular fitness,” *Front Immunol*, vol. 5, no. AUG, 2014, doi: 10.3389/fimmu.2014.00403.

- [177] A. M. K. Choi, S. W. Ryter, and B. Levine, “Autophagy in Human Health and Disease,” *New England Journal of Medicine*, vol. 368, no. 7, pp. 651–662, Feb. 2013, doi: 10.1056/nejmra1205406.
- [178] J. A. Lee, A. Beigneux, S. T. Ahmad, S. G. Young, and F. B. Gao, “ESCRT-III Dysfunction Causes Autophagosome Accumulation and Neurodegeneration,” *Current Biology*, vol. 17, no. 18, pp. 1561–1567, Sep. 2007, doi: 10.1016/j.cub.2007.07.029.
- [179] G. Skibinski *et al.*, “Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia,” *Nat Genet*, vol. 37, no. 8, pp. 806–808, Aug. 2005, doi: 10.1038/ng1609.
- [180] M. Filimonenko *et al.*, “Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease,” *Journal of Cell Biology*, vol. 179, no. 3, pp. 485–500, Nov. 2007, doi: 10.1083/jcb.200702115.
- [181] A. Kalani, A. Tyagi, and N. Tyagi, “Exosomes: Mediators of neurodegeneration, neuroprotection and therapeutics,” *Molecular Neurobiology*, vol. 49, no. 1. Humana Press Inc., pp. 590–600, 2014. doi: 10.1007/s12035-013-8544-1.
- [182] K. M. Danzer *et al.*, “Exosomal cell-to-cell transmission of alpha synuclein oligomers,” *Mol Neurodegener*, vol. 7, no. 1, 2012, doi: 10.1186/1750-1326-7-42.
- [183] C. A. Bader, T. Shandala, Y. S. Ng, I. R. D. Johnson, and D. A. Brooks, “Atg9 is required for intraluminal vesicles in amphisomes and autolysosomes,” *Biol Open*, vol. 4, no. 11, pp. 1345–1355, 2015, doi: 10.1242/bio.013979.
- [184] H. Guo *et al.*, “Atg5 Disassociates the V1V0-ATPase to Promote Exosome Production and Tumor Metastasis Independent of Canonical Macroautophagy,” *Dev Cell*, vol. 43, no. 6, pp. 716–730.e7, Dec. 2017, doi: 10.1016/j.devcel.2017.11.018.
- [185] L. Murrow, R. Malhotra, and J. Debnath, “ATG12-ATG3 interacts with Alix to promote basal autophagic flux and late endosome function,” *Nat Cell Biol*, vol. 17, no. 3, pp. 300–310, Mar. 2015, doi: 10.1038/ncb3112.
- [186] C. Villarroya-Beltri *et al.*, “ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins,” *Nat Commun*, vol. 7, Nov. 2016, doi: 10.1038/ncomms13588.
- [187] S. N. Hurwitz, M. R. Cheerathodi, D. Nkosi, S. B. York, and D. G. Meckes, “Tetraspanin CD63 Bridges Autophagic and Endosomal Processes To Regulate Exosomal Secretion and Intracellular Signaling of Epstein-Barr Virus LMP1,” 2018. [Online]. Available: <https://doi.org/10.1038/ncomms13588>
- [188] A. M. Poehler *et al.*, “Autophagy modulates SNCA/ α -synuclein release, thereby generating a hostile microenvironment,” *Autophagy*, vol. 10, no. 12, pp. 2171–2192, Dec. 2014, doi: 10.4161/auto.36436.
- [189] C. F. Bento, A. Ashkenazi, M. Jimenez-Sanchez, and D. C. Rubinsztein, “The Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway,” *Nat Commun*, vol. 7, Jun. 2016, doi: 10.1038/ncomms11803.
- [190] L. Alvarez-Erviti *et al.*, “Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission,” *Neurobiol Dis*, vol. 42, no. 3, pp. 360–367, Jun. 2011, doi: 10.1016/j.nbd.2011.01.029.
- [191] G. Minakaki *et al.*, “Autophagy inhibition promotes SNCA/ α -synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype,” *Autophagy*, vol. 14, no. 1, pp. 98–119, Jan. 2018, doi: 10.1080/15548627.2017.1395992.
- [192] J. Huotari and A. Helenius, “Endosome maturation,” *EMBO Journal*, vol. 30, no. 17, pp. 3481–3500, Aug. 31, 2011. doi: 10.1038/emboj.2011.286.
- [193] M. Colombo, G. Raposo, and C. Théry, “Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles,” *Annual review of cell and developmental biology*, vol. 30, pp. 255–289, 2014. doi: 10.1146/annurev-cellbio-101512-122326.

- [194] M. S. Kostelansky *et al.*, “Molecular Architecture and Functional Model of the Complete Yeast ESCRT-I Heterotetramer,” *Cell*, vol. 129, no. 3, pp. 485–498, May 2007, doi: 10.1016/j.cell.2007.03.016.
- [195] D. J. Katzmann, C. J. Stefan, M. Babst, and S. D. Emr, “Vps27 recruits ESCRT machinery to endosomes during MVB sorting,” *Journal of Cell Biology*, vol. 162, no. 3, pp. 413–423, Aug. 2003, doi: 10.1083/jcb.200302136.
- [196] D. J. Gill *et al.*, “Structural insight into the ESCRT-I/-II link and its role in MVB trafficking,” *EMBO Journal*, vol. 26, no. 2, pp. 600–612, Jan. 2007, doi: 10.1038/sj.emboj.7601501.
- [197] G. Odorizzi, “The multiple personalities of Alix,” *J Cell Sci*, vol. 119, no. 15, pp. 3025–3032, Aug. 2006, doi: 10.1242/jcs.03072.
- [198] S. Saksena, J. Wahlman, D. Teis, A. E. Johnson, and S. D. Emr, “Functional Reconstitution of ESCRT-III Assembly and Disassembly,” *Cell*, vol. 136, no. 1, pp. 97–109, Jan. 2009, doi: 10.1016/j.cell.2008.11.013.
- [199] T. Wollert, C. Wunder, J. Lippincott-Schwartz, and J. H. Hurley, “Membrane scission by the ESCRT-III complex,” *Nature*, vol. 458, no. 7235, pp. 172–177, Mar. 2009, doi: 10.1038/nature07836.
- [200] N. Jouvenet, M. Zhadina, P. D. Bieniasz, and S. M. Simon, “Dynamics of ESCRT protein recruitment during retroviral assembly,” *Nat Cell Biol*, vol. 13, no. 4, pp. 394–402, Apr. 2011, doi: 10.1038/ncb2207.
- [201] K. Katoh *et al.*, “The ALG-2-interacting protein Alix associates with CHMP4b, a human homologue of yeast Snf7 that is involved in multivesicular body sorting,” *Journal of Biological Chemistry*, vol. 278, no. 40, pp. 39104–39113, Oct. 2003, doi: 10.1074/jbc.M301604200.
- [202] M. F. Baietti *et al.*, “Syndecan-syntenin-ALIX regulates the biogenesis of exosomes,” *Nat Cell Biol*, vol. 14, no. 7, pp. 677–685, Jul. 2012, doi: 10.1038/ncb2502.
- [203] M. Colombo *et al.*, “Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles,” *J Cell Sci*, vol. 126, no. 24, pp. 5553–5565, Dec. 2013, doi: 10.1242/jcs.128868.
- [204] S. Stuffers, C. Sem Wegner, H. Stenmark, and A. Brech, “Multivesicular endosome biogenesis in the absence of ESCRTs,” *Traffic*, vol. 10, no. 7, pp. 925–937, 2009, doi: 10.1111/j.1600-0854.2009.00920.x.
- [205] Katarina Trajkovic *et al.*, “Ceramide triggers budding of exosome vesicles into multivesicular endosomes,” *Science (1979)*, vol. 319, no. 5867, pp. 1241–1244, Feb. 2008, doi: 10.1126/science.1152505.
- [206] S. Phuyal, N. P. Hessvik, T. Skotland, K. Sandvig, and A. Llorente, “Regulation of exosome release by glycosphingolipids and flotillins,” *FEBS Journal*, vol. 281, no. 9, pp. 2214–2227, 2014, doi: 10.1111/febs.12775.
- [207] K. Laulagnier *et al.*, “PLD2 is enriched on exosomes and its activity is correlated to the release of exosomes,” *FEBS Lett*, vol. 572, no. 1–3, pp. 11–14, Aug. 2004, doi: 10.1016/j.febslet.2004.06.082.
- [208] H. Matsuo *et al.*, “Role of LBPA and Alix in Multivesicular Liposome Formation and Endosome Organization,” 1995. [Online]. Available: www.sciencemag.org/cgi/content/full/303/5657/527/
- [209] G. van Niel *et al.*, “The Tetraspanin CD63 Regulates ESCRT-Independent and -Dependent Endosomal Sorting during Melanogenesis,” *Dev Cell*, vol. 21, no. 4, pp. 708–721, Oct. 2011, doi: 10.1016/j.devcel.2011.08.019.
- [210] A. Chairoungdua, D. L. Smith, P. Pochard, M. Hull, and M. J. Caplan, “Exosome release of β -catenin: A novel mechanism that antagonizes Wnt signaling,” *Journal of Cell Biology*, vol. 190, no. 6, pp. 1079–1091, Sep. 2010, doi: 10.1083/jcb.201002049.
- [211] T. Hasegawa *et al.*, “The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α -synuclein,” *PLoS One*, vol. 6, no. 12, Dec. 2011, doi: 10.1371/journal.pone.0029460.

- [212] B. Spencer *et al.*, “ α -synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease,” *Hum Mol Genet*, vol. 25, no. 6, pp. 1100–1115, Aug. 2015, doi: 10.1093/hmg/ddv633.
- [213] V. Sackmann *et al.*, “Inhibition of nSMase2 Reduces the Transfer of Oligomeric α -Synuclein Irrespective of Hypoxia,” *Front Mol Neurosci*, vol. 12, Aug. 2019, doi: 10.3389/fnmol.2019.00200.
- [214] C. Zhu *et al.*, “Pharmacological inhibition of nSMase2 reduces brain exosome release and α -synuclein pathology in a Parkinson’s disease model,” *Mol Brain*, vol. 14, no. 1, Dec. 2021, doi: 10.1186/s13041-021-00776-9.
- [215] M. Babst, D. J. Katzmann, W. B. Snyder, B. Wendland, and S. D. Emr, “Endosome-Associated Complex, ESCRT-II, Recruits Transport Machinery for Protein Sorting at the Multivesicular Body,” *Dev Cell*, vol. 3, pp. 283–289, 2002.
- [216] M. Babst, D. J. Katzmann, E. J. Estepa-Sabal, T. Meerloo, and S. D. Emr, “ESCRT-III: An Endosome-Associated Heterooligomeric Protein Complex Required for MVB Sorting,” 2002. [Online]. Available: <http://www>.
- [217] L. N. Ventimiglia and M. A. Alonso, “Biogenesis and function of T cell-derived exosomes,” *Frontiers in Cell and Developmental Biology*, vol. 4, no. AUG. Frontiers Media S.A., Aug. 17, 2016. doi: 10.3389/fcell.2016.00084.
- [218] L. Mashouri, H. Yousefi, A. R. Aref, A. M. Ahadi, F. Molaei, and S. K. Alahari, “Exosomes: Composition, biogenesis, and mechanisms in cancer metastasis and drug resistance,” *Molecular Cancer*, vol. 18, no. 1. BioMed Central Ltd., Apr. 02, 2019. doi: 10.1186/s12943-019-0991-5.
- [219] H. Wei *et al.*, “Regulation of exosome production and cargo sorting,” *Int J Biol Sci*, vol. 17, no. 1, pp. 163–177, 2020, doi: 10.7150/ijbs.53671.
- [220] S. Mathivanan, C. J. Fahner, G. E. Reid, and R. J. Simpson, “ExoCarta 2012: Database of exosomal proteins, RNA and lipids,” *Nucleic Acids Res*, vol. 40, no. D1, Jan. 2012, doi: 10.1093/nar/gkr828.
- [221] J. Zhang *et al.*, “Exosome and exosomal microRNA: Trafficking, sorting, and function,” *Genomics, Proteomics and Bioinformatics*, vol. 13, no. 1. Beijing Genomics Institute, pp. 17–24, Feb. 01, 2015. doi: 10.1016/j.gpb.2015.02.001.
- [222] D. P. Vlachakis, K. I. Diakou, and G. P. Chrousos, “Future of Exosome Bioinformatics,” *EMBnet J*, vol. 28, p. e1015, Mar. 2023, doi: 10.14806/ej.28.0.1015.
- [223] M. R. Fernando, C. Jiang, G. D. Krzyzanowski, and W. L. Ryan, “New evidence that a large proportion of human blood plasma cell-free DNA is localized in exosomes,” *PLoS One*, vol. 12, no. 8, Aug. 2017, doi: 10.1371/journal.pone.0183915.
- [224] P. Sansone *et al.*, “Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer,” *Proc Natl Acad Sci U S A*, vol. 114, no. 43, pp. E9066–E9075, Oct. 2017, doi: 10.1073/pnas.1704862114.
- [225] R. Kalluri and V. S. Lebleu, “Discovery of double-stranded genomic DNA in circulating exosomes,” *Cold Spring Harb Symp Quant Biol*, vol. 81, no. 1, pp. 275–280, 2016, doi: 10.1101/sqb.2016.81.030932.
- [226] Y. Wu, W. Deng, and D. J. Klinke, “Exosomes: Improved methods to characterize their morphology, RNA content, and surface protein biomarkers,” *Analyst*, vol. 140, no. 19, pp. 6631–6642, Oct. 2015, doi: 10.1039/c5an00688k.
- [227] K. Ariyoshi, T. Miura, K. Kasai, Y. Fujishima, A. Nakata, and M. Yoshida, “Radiation-Induced Bystander Effect is Mediated by Mitochondrial DNA in Exosome-Like Vesicles,” *Sci Rep*, vol. 9, no. 1, Dec. 2019, doi: 10.1038/s41598-019-45669-z.
- [228] M. Guescini *et al.*, “C2C12 myoblasts release micro-vesicles containing mtDNA and proteins involved in signal transduction,” *Exp Cell Res*, vol. 316, no. 12, pp. 1977–1984, 2010, doi: 10.1016/j.yexcr.2010.04.006.

- [229] M. F. Bolukbasi *et al.*, “MiR-1289 and ‘zipcode’-like sequence enrich mRNAs in microvesicles,” *Mol Ther Nucleic Acids*, vol. 1, no. 2, p. e10, 2012, doi: 10.1038/mtna.2011.2.
- [230] O. A. Kossinova *et al.*, “Cytosolic YB-1 and NSUN2 are the only proteins recognizing specific motifs present in mRNAs enriched in exosomes,” *Biochim Biophys Acta Proteins Proteom*, vol. 1865, no. 6, pp. 664–673, Jun. 2017, doi: 10.1016/j.bbapap.2017.03.010.
- [231] M. Varela-Eirin *et al.*, “Recruitment of RNA molecules by connexin RNA-binding motifs: Implication in RNA and DNA transport through microvesicles and exosomes,” *Biochimica et Biophysica Acta - Molecular Cell Research*, vol. 1864, no. 4. Elsevier B.V., pp. 728–736, Apr. 01, 2017. doi: 10.1016/j.bbamcr.2017.02.001.
- [232] L. F. Gulyaeva and N. E. Kushlinskiy, “Regulatory mechanisms of microRNA expression,” *Journal of Translational Medicine*, vol. 14, no. 1. BioMed Central Ltd., May 20, 2016. doi: 10.1186/s12967-016-0893-x.
- [233] C. Villarroya-Beltri *et al.*, “Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs,” *Nat Commun*, vol. 4, Dec. 2013, doi: 10.1038/ncomms3980.
- [234] A. Zietzer *et al.*, “The RNA-binding protein hnRNPU regulates the sorting of microRNA-30c-5p into large extracellular vesicles,” *J Extracell Vesicles*, vol. 9, no. 1, Jan. 2020, doi: 10.1080/20013078.2020.1786967.
- [235] J. Pérez-Boza, A. Boeckx, M. Lion, F. Dequiedt, and I. Struman, “hnRNPA2B1 inhibits the exosomal export of miR-503 in endothelial cells,” *Cellular and Molecular Life Sciences*, vol. 77, no. 21, pp. 4413–4428, Nov. 2020, doi: 10.1007/s00018-019-03425-6.
- [236] L. Santangelo *et al.*, “The RNA-Binding Protein SYNCRIP Is a Component of the Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting,” *Cell Rep*, vol. 17, no. 3, pp. 799–808, Oct. 2016, doi: 10.1016/j.celrep.2016.09.031.
- [237] F. Lin *et al.*, “YBX-1 mediated sorting of miR-133 into hypoxia/reoxygenation-induced EPC-derived exosomes to increase fibroblast angiogenesis and MEndoT,” *Stem Cell Res Ther*, vol. 10, no. 1, Aug. 2019, doi: 10.1186/s13287-019-1377-8.
- [238] M. Shurtleff, M. Temoche-Diaz, K. Karfilis, S. Ri, and R. Schekman, “Y-box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction,” *Elife*, 2016, doi: DOI: 10.7554/eLife.19276.
- [239] S. Ramanathan *et al.*, “Inflammation potentiates miR-939 expression and packaging into small extracellular vesicles,” *J Extracell Vesicles*, vol. 8, no. 1, Dec. 2019, doi: 10.1080/20013078.2019.1650595.
- [240] A. L. Wozniak *et al.*, “The RNA binding protein FMR1 controls selective exosomal miRNA cargo loading during inflammation,” *Journal of Cell Biology*, vol. 219, no. 10, 2020, doi: 10.1083/JCB.201912074.
- [241] D. Koppers-Lalic *et al.*, “Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes,” *Cell Rep*, vol. 8, no. 6, pp. 1649–1658, Sep. 2014, doi: 10.1016/j.celrep.2014.08.027.
- [242] M. M. Temoche-Diaz *et al.*, “Distinct mechanisms of microRNA sorting into cancer cell-derived extracellular vesicle subtypes,” 2019, doi: 10.7554/eLife.47544.001.
- [243] J. R. Chevillet *et al.*, “Quantitative and stoichiometric analysis of the microRNA content of exosomes,” *Proc Natl Acad Sci U S A*, vol. 111, no. 41, pp. 14888–14893, Oct. 2014, doi: 10.1073/pnas.1408301111.
- [244] L. Morel *et al.*, “Neuronal exosomal mirna-dependent translational regulation of astroglial glutamate transporter glt1,” *Journal of Biological Chemistry*, vol. 288, no. 10, pp. 7105–7116, Mar. 2013, doi: 10.1074/jbc.M112.410944.

- [245] J. C. Dugas *et al.*, “Dicer1 and miR-219 Are Required for Normal Oligodendrocyte Differentiation and Myelination,” *Neuron*, vol. 65, no. 5, pp. 597–611, Mar. 2010, doi: 10.1016/j.neuron.2010.01.027.
- [246] A. D. Pusic and R. P. Kraig, “Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination,” *Glia*, vol. 62, no. 2, pp. 284–299, Feb. 2014, doi: 10.1002/glia.22606.
- [247] K. J. McMillan *et al.*, “Loss of MicroRNA-7 Regulation Leads to α -Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo,” *Molecular Therapy*, vol. 25, no. 10, pp. 2404–2414, Oct. 2017, doi: 10.1016/j.ymthe.2017.08.017.
- [248] Y. Chen *et al.*, “MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson’s disease,” *Front Aging Neurosci*, vol. 9, no. JUL, Jul. 2017, doi: 10.3389/fnagi.2017.00232.
- [249] Y. Jiang *et al.*, “Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson’s disease,” *Brain Res*, vol. 1722, Nov. 2019, doi: 10.1016/j.brainres.2019.146331.
- [250] N. Shakespear, M. Ogura, J. Yamaki, and Y. Homma, “Astrocyte-Derived Exosomal microRNA miR-200a-3p Prevents MPP+-Induced Apoptotic Cell Death Through Down-Regulation of MKK4,” *Neurochem Res*, vol. 45, no. 5, pp. 1020–1033, May 2020, doi: 10.1007/s11064-020-02977-5.
- [251] X. Y. Cao *et al.*, “MicroRNA biomarkers of Parkinson’s disease in serum exosome-like microvesicles,” *Neurosci Lett*, vol. 644, pp. 94–99, Mar. 2017, doi: 10.1016/j.neulet.2017.02.045.
- [252] Y. Yao, M. Qu, G. Li, F. Zhang, and H. Rui, “Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson’s disease,” *Eur Rev Med Pharmacol Sci*, vol. 22, pp. 5278–5283, 2018.
- [253] M. Cristina *et al.*, “miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease,” 2018. [Online]. Available: www.oncotarget.com
- [254] C. Barbagallo *et al.*, “Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases,” *Cell Mol Neurobiol*, vol. 40, no. 4, pp. 531–546, May 2020, doi: 10.1007/s10571-019-00751-y.
- [255] S. Xie, W. Niu, F. Xu, Y. Wang, S. Hu, and C. Niu, “Differential expression and significance of miRNAs in plasma extracellular vesicles of patients with Parkinson’s disease,” *International Journal of Neuroscience*, vol. 132, no. 7, pp. 673–688, 2022, doi: 10.1080/00207454.2020.1835899.
- [256] I. Grossi *et al.*, “MicroRNA-34a-5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson’s disease: An exploratory study,” *Int J Mol Med*, vol. 47, no. 2, pp. 533–546, Feb. 2021, doi: 10.3892/ijmm.2020.4806.
- [257] G. Van Niel, G. D’Angelo, and G. Raposo, “Shedding light on the cell biology of extracellular vesicles,” *Nature Reviews Molecular Cell Biology*, vol. 19, no. 4. Nature Publishing Group, pp. 213–228, Apr. 01, 2018. doi: 10.1038/nrm.2017.125.
- [258] L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhali, and M. J. A. Wood, “Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes,” *Nat Biotechnol*, vol. 29, no. 4, pp. 341–345, Apr. 2011, doi: 10.1038/nbt.1807.
- [259] J. M. Cooper *et al.*, “Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice,” *Movement Disorders*, vol. 29, no. 12, pp. 1476–1485, Oct. 2014, doi: 10.1002/mds.25978.
- [260] R. Kojima *et al.*, “Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment,” *Nat Commun*, vol. 9, no. 1, Dec. 2018, doi: 10.1038/s41467-018-03733-8.
- [261] C. Saraiva, J. Paiva, T. Santos, L. Ferreira, and L. Bernardino, “MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson’s disease,” *Journal of Controlled Release*, vol. 235, pp. 291–305, Aug. 2016, doi: 10.1016/j.jconrel.2016.06.005.

- [262] C. Frühbeis, D. Fröhlich, W. P. Kuo, and E. M. Krämer-Albers, “Extracellular vesicles as mediators of neuron-glia communication,” *Frontiers in Cellular Neuroscience*, no. OCT. Oct. 30, 2013. doi: 10.3389/fncel.2013.00182.
- [263] P. Desplats *et al.*, “Inclusion formation and neuronal cell death through neuron-to-neuron transmission of-synuclein.” [Online]. Available: www.pnas.org/cgi/content/full/
- [264] H. J. Lee *et al.*, “Direct transfer of α -synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies,” *Journal of Biological Chemistry*, vol. 285, no. 12, pp. 9262–9272, Mar. 2010, doi: 10.1074/jbc.M109.081125.
- [265] N. Plotegher and M. R. Duchen, “Crosstalk between lysosomes and mitochondria in Parkinson’s disease,” *Frontiers in Cell and Developmental Biology*, vol. 5, no. DEC. Frontiers Media S.A., Dec. 12, 2017. doi: 10.3389/fcell.2017.00110.
- [266] H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall, “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells,” *Nat Cell Biol*, vol. 9, no. 6, pp. 654–659, Jun. 2007, doi: 10.1038/ncb1596.
- [267] L. A. Volpicelli-Daley, K. C. Luk, and V. M. Y. Lee, “Addition of exogenous α -synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α -synuclein to Lewy body and Lewy neurite-like aggregates,” *Nature Protocols*, vol. 9, no. 9. Nature Publishing Group, pp. 2135–2146, 2014. doi: 10.1038/nprot.2014.143.
- [268] J. P. Wise and J. Cannon, “Alterations in optineurin expression and localization in pre-clinical Parkinson’s disease models,” *Toxicological Sciences*, vol. 153, no. 2, pp. 372–381, Oct. 2016, doi: 10.1093/toxsci/kfw133.
- [269] J. H. Yang, J. H. Li, P. Shao, H. Zhou, Y. Q. Chen, and L. H. Qu, “StarBase: A database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data,” *Nucleic Acids Res*, vol. 39, no. SUPPL. 1, Jan. 2011, doi: 10.1093/nar/gkq1056.
- [270] G. Dennis *et al.*, “DAVID: Database for Annotation, Visualization, and Integrated Discovery,” 2003. [Online]. Available: <http://dot.ped.med.umich.edu:2000/>
- [271] J. Jordán, M. F. Galindo, D. Tornero, C. González-García, and V. Ceña, “Bcl-xL blocks mitochondrial multiple conductance channel activation and inhibits 6-OHDA-induced death in SH-SY5Y cells,” *J Neurochem*, vol. 89, no. 1, pp. 124–133, 2004, doi: 10.1046/j.1471-4159.2003.02299.x.
- [272] N. Xiong *et al.*, “Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson’s disease models,” *Critical Reviews in Toxicology*, vol. 42, no. 7. pp. 613–632, Aug. 2012. doi: 10.3109/10408444.2012.680431.
- [273] Savina A, Vidal M, and Colombo MI, “The exosome pathway in K562 cells is regulated by Rab11,” *J Cell Sci*, vol. 115, no. 12, pp. 2505–2515, 2002.
- [274] F. Baixauli *et al.*, “Mitochondrial respiration controls lysosomal function during inflammatory t cell responses,” *Cell Metab*, vol. 22, no. 3, pp. 485–498, Sep. 2015, doi: 10.1016/j.cmet.2015.07.020.
- [275] C. J. Cortes and A. R. La Spada, “TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: Molecular mechanisms, cellular processes, and emerging therapeutic opportunities,” *Neurobiology of Disease*, vol. 122. Academic Press Inc., pp. 83–93, Feb. 01, 2019. doi: 10.1016/j.nbd.2018.05.012.
- [276] Z. H. Cheung and N. Y. Ip, “The emerging role of autophagy in Parkinson’s disease,” *Molecular Brain*, vol. 2, no. 1. 2009. doi: 10.1186/1756-6606-2-29.
- [277] S. Kimura, T. Noda, and T. Yoshimori, “Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3,” *Autophagy*, vol. 3, no. 5, pp. 452–460, 2007, doi: 10.4161/auto.4451.

- [278] S. Chittaranjan, S. Bortnik, and S. M. Gorski, "Monitoring autophagic flux by using lysosomal inhibitors and western blotting of endogenous MAP1LC3B," *Cold Spring Harb Protoc*, vol. 2015, no. 8, pp. 743–750, Aug. 2015, doi: 10.1101/pdb.prot086256.
- [279] J. Xu, R. Camfield, and S. M. Gorski, "The interplay between exosomes and autophagy - partners in crime," *Journal of Cell Science*, vol. 131, no. 15. Company of Biologists Ltd, Aug. 01, 2018. doi: 10.1242/jcs.215210.
- [280] C. Malagelada, Z. H. Jin, V. Jackson-Lewis, S. Przedborski, and L. A. Greene, "Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease," *Journal of Neuroscience*, vol. 30, no. 3, pp. 1166–1175, Jan. 2010, doi: 10.1523/JNEUROSCI.3944-09.2010.
- [281] A. Garrett, "Biology of Parkinson's disease - pathogenesis and pathophysiology of a multisystem neurodegenerative disorder," *Dialogues Clin Neurosci*, vol. 6, no. 3, 2004.
- [282] J. W. Langston *et al.*, "Evidence of Active Nerve Cell Degeneration in the Substantia Nigra of Humans Years after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Exposure," 1999.
- [283] D. M. Bronstein *et al.*, "Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures," ELSEVIER, 1995.
- [284] W.-G. Kim, R. P. Mohney, B. Wilson, G.-H. Jeohn, B. Liu, and J.-S. Hong, "Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia," 2000.
- [285] D. J. Surmeier and P. T. Schumacker, "Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease," *Journal of Biological Chemistry*, vol. 288, no. 15. pp. 10736–10741, Apr. 12, 2013. doi: 10.1074/jbc.R112.410530.
- [286] K. Nakamura *et al.*, "Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein α -synuclein," *Journal of Biological Chemistry*, vol. 286, no. 23, pp. 20710–20726, Jun. 2011, doi: 10.1074/jbc.M110.213538.
- [287] L. Devi, V. Raghavendran, B. M. Prabhu, N. G. Avadhani, and H. K. Anandatheerthavarada, "Mitochondrial import and accumulation of α -synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain," *Journal of Biological Chemistry*, vol. 283, no. 14, pp. 9089–9100, Apr. 2008, doi: 10.1074/jbc.M710012200.
- [288] P. M. Keeney, J. Xie, R. A. Capaldi, and J. P. Bennett, "Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled," *Journal of Neuroscience*, vol. 26, no. 19, pp. 5256–5264, 2006, doi: 10.1523/JNEUROSCI.0984-06.2006.
- [289] P. Chan, L. E. Delaney, I. Irwin, J. W. Langston, and D. Di Monte, "Rapid Communication Rapid ATP Loss Caused by 1-Methyl-4-Phenyl-1,2,3,6," Neurochemistry Raven Press, Ltd, 1991.
- [290] L. Tretter, I. Sipos, and V. Adam-Vizi, "Initiation of Neuronal Damage by Complex I Deficiency and Oxidative Stress in Parkinson's Disease*," 2004.
- [291] W. Davis Parker, T. J. Sally Boyson, and J. K. Parks, "Abnormahties of the Electron Transport Chain in Idiopathrc Pukmson's Disease," 1989.
- [292] L. Polito, A. Greco, and D. Seripa, "Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease," *Parkinson's Disease*, vol. 2016. Hindawi Limited, 2016. doi: 10.1155/2016/6465793.
- [293] P. V. Ramachandran *et al.*, "Lysosomal Signaling Promotes Longevity by Adjusting Mitochondrial Activity," *Dev Cell*, vol. 48, no. 5, pp. 685-696.e5, Mar. 2019, doi: 10.1016/j.devcel.2018.12.022.
- [294] R. Horbay, A. Hamraghani, L. Ermini, S. Holcik, S. T. Beug, and B. Yeganeh, "Role of Ceramides and Lysosomes in Extracellular Vesicle Biogenesis, Cargo Sorting and Release," *International Journal of Molecular Sciences*, vol. 23, no. 23. MDPI, Dec. 01, 2022. doi: 10.3390/ijms232315317.
- [295] W. Liang *et al.*, "Mitochondria are secreted in extracellular vesicles when lysosomal function is impaired," *Nat Commun*, vol. 14, no. 1, Dec. 2023, doi: 10.1038/s41467-023-40680-5.

- [296] X. Ma *et al.*, “Mitochondria-lysosome-related organelles mediate mitochondrial clearance during cellular dedifferentiation,” *Cell Rep*, vol. 42, no. 10, Oct. 2023, doi: 10.1016/j.celrep.2023.113291.
- [297] H. Martini-Stoica, Y. Xu, A. Ballabio, and H. Zheng, “The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective,” *Trends in Neurosciences*, vol. 39, no. 4. Elsevier Ltd, pp. 221–234, Apr. 01, 2016. doi: 10.1016/j.tins.2016.02.002.
- [298] T. Kataura *et al.*, “Autophagy promotes cell survival by maintaining NAD levels,” *Dev Cell*, vol. 57, no. 22, pp. 2584-2598.e11, Nov. 2022, doi: 10.1016/j.devcel.2022.10.008.
- [299] S. Shukla *et al.*, “hsa-miR-320a mediated exosome release under PD stress conditions rescue mitochondrial ROS and cell death in the recipient neuronal and glial cells,” *International Journal of Biochemistry and Cell Biology*, vol. 162, Sep. 2023, doi: 10.1016/j.biocel.2023.106439.
- [300] D. Lin *et al.*, “Mesenchymal stem cells exosomal let-7a-5p improve autophagic flux and alleviate liver injury in acute-on-chronic liver failure by promoting nuclear expression of TFEB,” *Cell Death Dis*, vol. 13, no. 10, Oct. 2022, doi: 10.1038/s41419-022-05303-9.
- [301] N. Jaber *et al.*, “Vps34 regulates Rab7 and late endocytic trafficking through recruitment of the GTPase activating protein Armus Summary statement Vps34 regulates Rab7 and late stages of endocytosis,” 2016.
- [302] C. Frühbeis, D. Fröhlich, W. P. Kuo, and E. M. Krämer-Albers, “Extracellular vesicles as mediators of neuron-glia communication,” *Front Cell Neurosci*, no. 7, p. 182, Oct. 2013, doi: 10.3389/fncel.2013.00182.
- [303] C. Y. Guo, L. Sun, X. P. Chen, and D. S. Zhang, “Oxidative stress, mitochondrial damage and neurodegenerative diseases,” *Neural Regen Res*, vol. 8, no. 21, pp. 2003–2014, Jul. 2013, doi: 10.3969/j.issn.1673-5374.2013.21.009.
- [304] J. Zhang *et al.*, “Exosome and exosomal microRNA: Trafficking, sorting, and function,” *Genomics Proteomics Bioinformatics*, vol. 13, no. 1, pp. 17–24, Feb. 2015, doi: 10.1016/j.gpb.2015.02.001.
- [305] G. M. Halliday and C. H. Stevens, “Glial: Initiators and Progressors of Pathology in Parkinson’s Disease”, doi: 10.1002/23455.
- [306] M. Izco, E. Carlos, and L. Alvarez-Erviti, “The Two Faces of Exosomes in Parkinson’s Disease: From Pathology to Therapy,” *Neuroscientist*, vol. 28, no. 2. SAGE Publications Inc., pp. 180–193, Apr. 01, 2022. doi: 10.1177/1073858421990001.
- [307] D. Sepúlveda, M. Cisternas-Olmedo, J. Arcos, M. Nassif, and R. L. Vidal, “Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinson’s Disease,” *Frontiers in Molecular Neuroscience*, vol. 15. Frontiers Media S.A., Feb. 17, 2022. doi: 10.3389/fnmol.2022.805087.
- [308] M. Chivet, C. Javalet, K. Laulagnier, B. Blot, F. J. Hemming, and R. Sadoul, “Exosomes secreted by cortical neurons upon glutamatergic synapse activation specifically interact with neurons,” *J Extracell Vesicles*, vol. 3, no. 1, 2014, doi: 10.3402/jev.v3.24722.
- [309] T. Tian, Y. Wang, H. Wang, Z. Zhu, and Z. Xiao, “Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy,” *J Cell Biochem*, vol. 111, no. 2, pp. 488–496, Oct. 2010, doi: 10.1002/jcb.22733.
- [310] T. Tian, Y. L. Zhu, F. H. Hu, Y. Y. Wang, N. P. Huang, and Z. D. Xiao, “Dynamics of exosome internalization and trafficking,” *J Cell Physiol*, vol. 228, no. 7, pp. 1487–1495, Jul. 2013, doi: 10.1002/jcp.24304.
- [311] M. Izco, E. Carlos, and L. Alvarez-Erviti, “The Two Faces of Exosomes in Parkinson’s Disease: From Pathology to Therapy,” *Neuroscientist*, vol. 28, no. 2, pp. 180–193, Apr. 2022, doi: 10.1177/1073858421990001.
- [312] E. D. Pastuzyn *et al.*, “The Neuronal Gene Arc Encodes a Repurposed Retrotransposon Gag Protein that Mediates Intercellular RNA Transfer,” *Cell*, vol. 172, no. 1–2, pp. 275-288.e18, Jan. 2018, doi: 10.1016/j.cell.2017.12.024.

- [313] L. Sripada, D. Tomar, and R. Singh, "Mitochondria: One of the destinations of miRNAs," *Mitochondrion*, vol. 12, no. 6, pp. 593–599, Nov. 2012, doi: 10.1016/j.mito.2012.10.009.
- [314] L. Sripada, D. Tomar, P. Prajapati, R. Singh, A. K. Singh, and R. Singh, "Systematic Analysis of Small RNAs Associated with Human Mitochondria by Deep Sequencing: Detailed Analysis of Mitochondrial Associated miRNA," *PLoS One*, vol. 7, no. 9, Sep. 2012, doi: 10.1371/journal.pone.0044873.
- [315] R. Kuthethur *et al.*, "Expression analysis and function of mitochondrial genome-encoded microRNAs," *J Cell Sci*, vol. 135, no. 8, Apr. 2022, doi: 10.1242/jcs.258937.
- [316] W. X. Wang *et al.*, "Temporal changes in inflammatory mitochondria-enriched microRNAs following traumatic brain injury and effects of miR-146a nanoparticle delivery," *Neural Regen Res*, vol. 16, no. 3, pp. 514–522, Mar. 2021, doi: 10.4103/1673-5374.293149.
- [317] D. Li, H. Yang, J. Ma, S. Luo, S. Chen, and Q. Gu, "MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3," *Hum Cell*, vol. 31, no. 2, pp. 106–115, Apr. 2018, doi: 10.1007/s13577-017-0187-5.
- [318] A. D. Chaudhuri, D. C. Choi, S. Kabaria, A. Tran, and X. E. Junn, "MicroRNA-7 regulates the function of mitochondrial permeability transition pore by targeting vdac1 expression," *Journal of Biological Chemistry*, vol. 291, no. 12, pp. 6483–6493, Mar. 2016, doi: 10.1074/jbc.M115.691352.
- [319] E. Miñones-Moyano *et al.*, "MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function," *Hum Mol Genet*, vol. 20, no. 15, pp. 3067–3078, Aug. 2011, doi: 10.1093/hmg/ddr210.
- [320] A. B. Harbauer *et al.*, "Neuronal mitochondria transport Pink1 mRNA via synaptotagmin 2 to support local mitophagy," *Neuron*, vol. 110, no. 9, pp. 1516–1531.e9, May 2022, doi: 10.1016/j.neuron.2022.01.035.
- [321] D. A. Sliter *et al.*, "Parkin and PINK1 mitigate STING-induced inflammation," *Nature*, vol. 561, no. 7722, pp. 258–262, Sep. 2018, doi: 10.1038/s41586-018-0448-9.
- [322] A. Donato, K. Kagias, Y. Zhang, and M. A. Hilliard, "Neuronal sub-compartmentalization: a strategy to optimize neuronal function," *Biological Reviews*, vol. 94, no. 3, pp. 1023–1037, Jun. 2019, doi: 10.1111/brv.12487.
- [323] H. Teppola, J. R. Sarkanen, T. O. Jalonen, and M. L. Linne, "Morphological Differentiation Towards Neuronal Phenotype of SH-SY5Y Neuroblastoma Cells by Estradiol, Retinoic Acid and Cholesterol," *Neurochem Res*, vol. 41, no. 4, pp. 731–747, Apr. 2016, doi: 10.1007/s11064-015-1743-6.
- [324] S. Dwane, E. Durack, and P. A. Kiely, "Optimising parameters for the differentiation of SH-SY5Y cells to study cell adhesion and cell migration," *BMC Res Notes*, vol. 6, no. 1, 2013, doi: 10.1186/1756-0500-6-366.
- [325] M. L. Squadrito *et al.*, "Endogenous RNAs Modulate MicroRNA Sorting to Exosomes and Transfer to Acceptor Cells," *Cell Rep*, vol. 8, no. 5, pp. 1432–1446, 2014, doi: 10.1016/j.celrep.2014.07.035.
- [326] T. Janas, M. M. Janas, K. Sapoń, and T. Janas, "Mechanisms of RNA loading into exosomes," *FEBS Letters*, vol. 589, no. 13, Elsevier B.V., pp. 1391–1398, May 26, 2015. doi: 10.1016/j.febslet.2015.04.036.
- [327] S. Das *et al.*, "Nuclear miRNA regulates the mitochondrial genome in the heart," *Circ Res*, vol. 110, no. 12, pp. 1596–1603, Jun. 2012, doi: 10.1161/CIRCRESAHA.112.267732.
- [328] L. Li *et al.*, "miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect," *Cancer Lett*, vol. 400, pp. 89–98, Aug. 2017, doi: 10.1016/j.canlet.2017.04.034.
- [329] N. Dasgupta, Y. Peng, Z. Tan, G. Ciruolo, D. Wang, and R. Li, "miRNAs in mtDNA-less cell mitochondria," *Cell Death Discov*, vol. 1, no. 1, Dec. 2015, doi: 10.1038/cddiscovery.2015.4.

- [330] P. González-Rodríguez *et al.*, “Disruption of mitochondrial complex I induces progressive parkinsonism,” *Nature*, vol. 599, no. 7886, pp. 650–656, Nov. 2021, doi: 10.1038/s41586-021-04059-0.
- [331] P. Prajapati, L. Sripada, K. Singh, K. Bhatelia, R. Singh, and R. Singh, “TNF- α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells,” *Biochim Biophys Acta Mol Basis Dis*, vol. 1852, no. 3, pp. 451–461, Mar. 2015, doi: 10.1016/j.bbadis.2014.11.019.
- [332] S.-J. Yang, H.-R. Choi, J. S. Ha, E.-A. Kim, and S.-W. Cho, “Title: MiR-30a-5p and miR-153-3p regulate LPS-induced neuroinflammatory response and neuronal apoptosis by targeting NeuroD1,” *BMB Rep*, p. 5616, Jun. 2022, doi: In press; ePub ahead of print.
- [333] D. Siedlecki-Wullich *et al.*, “Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease,” *Alzheimers Res Ther*, vol. 11, no. 1, May 2019, doi: 10.1186/s13195-019-0501-4.
- [334] M. Zhang, L. Wang, S. Huang, and X. He, “Exosomes with high level of miR-181c from bone marrow-derived mesenchymal stem cells inhibit inflammation and apoptosis to alleviate spinal cord injury,” *J Mol Histol*, vol. 52, no. 2, pp. 301–311, Apr. 2021, doi: 10.1007/s10735-020-09950-0.
- [335] J. R. Cannon, V. Tapias, H. M. Na, A. S. Honick, R. E. Drolet, and J. T. Greenamyre, “A highly reproducible rotenone model of Parkinson’s disease,” *Neurobiol Dis*, vol. 34, no. 2, pp. 279–290, May 2009, doi: 10.1016/j.nbd.2009.01.016.
- [336] B. J. Ryan, S. Hoek, E. A. Fon, and R. Wade-Martins, “Mitochondrial dysfunction and mitophagy in Parkinson’s: From familial to sporadic disease,” *Trends in Biochemical Sciences*, vol. 40, no. 4. Elsevier Ltd, pp. 200–210, Apr. 01, 2015. doi: 10.1016/j.tibs.2015.02.003.
- [337] V. Bogaerts, J. Theuns, and C. Van Broeckhoven, “Genetic findings in Parkinson’s disease and translation into treatment: A leading role for mitochondria?,” *Genes, Brain and Behavior*, vol. 7, no. 2. pp. 129–151, Mar. 2008. doi: 10.1111/j.1601-183X.2007.00342.x.
- [338] E. Willms *et al.*, “Cells release subpopulations of exosomes with distinct molecular and biological properties,” *Sci Rep*, vol. 6, Mar. 2016, doi: 10.1038/srep22519.
- [339] H. Zhang *et al.*, “Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation,” *Nat Cell Biol*, vol. 20, no. 3, pp. 332–343, Mar. 2018, doi: 10.1038/s41556-018-0040-4.
- [340] A. D’Souza *et al.*, “Microvesicles transfer mitochondria and increase mitochondrial function in brain endothelial cells,” *Journal of Controlled Release*, vol. 338, pp. 505–526, Oct. 2021, doi: 10.1016/j.jconrel.2021.08.038.
- [341] L. Parnetti *et al.*, “CSF and blood biomarkers for Parkinson’s disease,” *The Lancet Neurology*, vol. 18, no. 6. Lancet Publishing Group, pp. 573–586, Jun. 01, 2019. doi: 10.1016/S1474-4422(19)30024-9.
- [342] J. G. Goldman *et al.*, “Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson’s disease Features,” *Movement Disorders*, vol. 33, no. 2, pp. 282–288, Feb. 2018, doi: 10.1002/mds.27232.
- [343] H. Ding *et al.*, “Identification of a panel of five serum miRNAs as a biomarker for Parkinson’s disease,” *Parkinsonism Relat Disord*, vol. 22, pp. 68–73, Jan. 2016, doi: 10.1016/j.parkreldis.2015.11.014.
- [344] L. F. Cardo *et al.*, “Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls,” *Journal of Neurology*, vol. 260, no. 5. pp. 1420–1422, May 2013. doi: 10.1007/s00415-013-6900-8.
- [345] Y. Li *et al.*, “Dynamic regulation of circulating microRNAs during acute exercise and long-term exercise training in basketball athletes,” *Front Physiol*, vol. 9, no. MAR, Mar. 2018, doi: 10.3389/fphys.2018.00282.

- [346] A. A. Ponomaryova *et al.*, “Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer,” *Exp Lung Res*, vol. 42, no. 2, pp. 95–102, Feb. 2016, doi: 10.3109/01902148.2016.1155245.
- [347] M. Abdelsalam, M. Ahmed, Z. Osaid, R. Hamoudi, and R. Harati, “Insights into Exosome Transport through the Blood–Brain Barrier and the Potential Therapeutical Applications in Brain Diseases,” *Pharmaceuticals*, vol. 16, no. 4. MDPI, Apr. 01, 2023. doi: 10.3390/ph16040571.
- [348] C. Gómez-Molina *et al.*, “Small Extracellular Vesicles in Rat Serum Contain Astrocyte-Derived Protein Biomarkers of Repetitive Stress,” *International Journal of Neuropsychopharmacology*, vol. 22, no. 3, pp. 232–246, Dec. 2018, doi: 10.1093/ijnp/pyy098.
- [349] Y. Wang, P. Jin, J. Liu, and X. Xie, “Exosomal microRNA-122 mediates obesity-related cardiomyopathy through suppressing mitochondrial ADP-ribosylation factor-like 2,” *Clin Sci*, vol. 133, no. 17, pp. 1871–1881, 2019, doi: 10.1042/CS20190558.
- [350] X. Chen *et al.*, “A20 protects neuronal apoptosis stimulated by lipopolysaccharide-induced microglial exosomes,” *Neurosci Lett*, vol. 712, Nov. 2019, doi: 10.1016/j.neulet.2019.134480.
- [351] C. Chang, H. Lang, N. Geng, J. Wang, N. Li, and X. Wang, “Exosomes of BV-2 cells induced by alpha-synuclein: Important mediator of neurodegeneration in PD,” *Neurosci Lett*, vol. 548, pp. 190–195, Aug. 2013, doi: 10.1016/j.neulet.2013.06.009.